Correlation of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) with Liver Transient Elastography Results: An Evaluating Liver Fibrosis in Chronic Hepatitis B Patients
), Muhammad Begawan Bestari(2), Nenny Agustanti(3), Dolvy Girawan(4), Yudi Wahyudi(5), Siti Aminah Abdurachman(6), Anna Tjandrawati(7),
(1) Division of Gastroenterology Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung
(2) Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung
(3) Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin Hospital, Bandung
(4) Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung
(5) Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung
(6) Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung
(7) Department of Clinical Pathology, Faculty of Medicine, Universitas Padjajaran/Dr. Hasan Sadikin General Hospital, Bandung
Corresponding Author
Abstract
Background: Transient elastography (TE) is widely recognized as a reliable surrogate marker for grading the severity of liver fibrosis in chronic hepatitis B (CHB) patients. Mac-2 binding protein of glycosylation isomer (M2BPGi) is a novel non-invasive serum biomarker for liver fibrosis staging in various liver diseases, including CHB. This study aimed to evaluate the correlation of M2BPGi and liver stiffness (LS), as measured through TE, in predicting the degree of liver fibrosis in CHB patients.
Methods: A cross-sectional study was conducted at Dr. Hasan Sadikin General Hospital, Bandung, between September 2021 and January 2022. The study included patients diagnosed with chronic hepatitis B (CHB) based on clinical and biochemical assessments. All subjects underwent TE examination using Fibroscan®, and the M2BPGi levels were determined with an automated immunoassay analyzer HISCL-800, Sysmex, Japan. Statistical analysis was conducted using the Spearman rank correlation method, with a significance value of p<0.05.
Results: A total of 119 patients with chronic hepatitis B (CHB) were consecutively recruited (Male:Female = 66:53; median age: 43 years). The median M2BPGi level was 1.04 COI (range: 0.74–1.59), while the median liver stiffness (LS) was 7.3 kPa (range: 5.6–12.5). A moderate and statistically significant correlation was observed between M2BPGi and LS (r = 0.525; p < 0.001). Median M2BPGi values by fibrosis stage were 0.89 COI for F0–F1, 0.88 for F2, 1.61 for F3, and 2.24 for F4 (p < 0.001).
Conclusion: This study revealed a moderate positive correlation between serum M2BPGi level and LS in CHB patients.
Keywords
References
World Health Organization. Fact sheet on hepatitis B. 2022. [cited 2022 July 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections. 2021. [serial online] [cited 2022 July 13]. Available from: https://www.who.int/publications/i/item/9789240027077
Wait S, Kell E, Hamid S, Muljono DH, Sollano J, Mohamed R, et al. Hepatitis B and hepatitis C in Southeast and Southern Asia: challenges for governments. The Lancet Gastroenterol Hepatol 2016;1:248–55.
Khan M, Dong JJ, Acharya SK, Dhagwahdorj Y, Abbas Z, Jafri S, et al. Hepatology issues in Asia: perspectives from regional leaders. J Gastroenterol Hepatol 2004;19:S419–30.
Muljono DH. Epidemiology of hepatitis B and C in Republic of Indonesia. Euroasian J Hepatogastroenterol 2017;7:55.
Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007;147:58–61.
Fattovich G, Flavia B, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–52.
Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003;23:47–58.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1.
Perhimpunan Peneliti Hati Indonesia. Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia. Jakarta: Perhimpunan Peneliti Hati Indonesia, 2017.
Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370–98.
Shipley LC, Axley PD, Singal AK. Liver fibrosis: a clinical update. EMJ Hepatol 2019;7:105–17.
Cheng JY-K, Wong GL-H. Advances in the diagnosis and treatment of liver fibrosis. Hepatoma Res 2017;3:156–69.
Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med 2017;5:40.
Saleh HA, Abu-Rashed AH. Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis. J Gastrointestin Liver Dis 2007;16:425–526.
Zeng DW, Zhang JM, Liu YR, Dong J, Jiang JJ, Zhu YY. A retrospective study on the significance of liver biopsy and hepatitis B surface antigen in chronic hepatitis B infection. Medicine 2016;95:e2503.
Mani H, Kleiner DE. Liver biopsy findings in chronic hepatitis B. Hepatology 2009;49:S61–71.
Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614–8.
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343–50.
Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol 2012;18:163–73.
Li Y, Huang YS, Wang ZZ, Yang ZR, Sun F, Zhan SY, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther 2016;43:458–69.
Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol 2018;53:819–26.
Toshima T, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis. J Gastroenterol 2014;50:76–84.
Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical utility of Mac-2 binding protein glycosylation isomer in chronic liver diseases. Ann Lab Med 2021;41:16–24.
Nishikawa H, Enomoto H, Iwata Y, Hasegawa K, Nakano C, Takata R, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res 2016;46:613–21.
Tsuji Y, Namisaki T, Kaji K, Takaya H, Nakanishi K, Sato S, et al. Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. Exp Ther Med 2020;20:985.
Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261.
Sanityoso A, Hasan I, Lesmana C, Kurniawan J, Jasirwan C, Nababab S. Accuracy of Mac-2 binding protein glycosylation isomer to assess liver stiffness in treatment naïve chronic hepatitis C patients in Indonesia. J Gastroenterol Hepatol 2021;36:x.
Mak LY, Wong DKH, Cheung KS, Seto WK, Lai CL, Yuen MF. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol 2018;9:163.
Horas S, Nababan H, Fariz KK, Jasirwan COM, Kurniawan J, Lesmana RA, et al. Mac-2 binding protein glycosylation isomer for screening high-risk esophageal varices in liver cirrhotic patient. Livers 2021;1:60–7.
Prasetyadi YL, Elsha A, Simbolon M, Permatasari AA, Swaraghani DR, Chairunisa S, et al. The role of Wisteria floribunda (M2BPGi) serum level for diagnosing liver fibrosis in hepatitis B patient: an evidence based case report. Indones J Gastroenterol Hepatol Digest Endosc 2019;20:129–33.
Pham TTT, Ho DT, Nguyen T. Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population. World J Hepatol 2020;12:220–9.
Kim M, Jun DW, Park H, Kang BK, Sumida Y. Sequential combination of FIB-4 followed by M2BPGi enhanced diagnostic performance for advanced hepatic fibrosis in an average risk population. J Clin Med 2020;9:1119.
Mak LY, Wong DKH, Cheung KS, Seto WK, Lai CL, Yuen MF. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol 2018;9:163.
Ishii A, Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, et al. Clinical implications of serum Wisteria floribunda agglutinin-positive Mac-2-binding protein in treatment-naïve chronic hepatitis B. Hepatol Res 2017;47:204–15.
Zou X, Zhu MY, Yu DM, Li W, Zhang DH, Lu FJ, et al. Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection. Liver Int 2017;37:35–44.
Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep 2014;16:372.
Mukaka MM. A guide to appropriate use of correlation coefficient in medical research. Malawi Med J 2012;24:69.
Kim H-Y. Statistical notes for clinical researchers: chi-squared test and Fisher’s exact test. Restor Dent Endod 2017;42:152.
Chan Y, Walmsley RP. Learning and understanding the Kruskal-Wallis one-way analysis-of-variance-by-ranks test for differences among three or more independent groups. Phys Ther 1997;77:1755–62.
Wei B, Feng S, Chen E, Li D, Wang T, Gou Y, et al. M2BPGi as a potential diagnostic tool of cirrhosis in Chinese patients with hepatitis B virus infection. J Clin Lab Anal 2018;32:e22261.
Yeh ML, Huang CF, Huang C, Dai CY, Lin IH, Liang PC, et al. Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. PLoS One 2019;14:e0220663.
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212–9.
Khan F, Shams S, Qureshi ID, Israr M, Khan H, Sarwar MT, et al. Hepatitis B virus infection among different sex and age groups in Pakistani Punjab. Virol J 2011;8:1–5.
Chu C-M, Liaw Y-F, Sheen I-S, Lin D-Y, Huang M-J. Sex difference in chronic hepatitis B virus infection: an appraisal based on the status of hepatitis B e antigen and antibody. Hepatology 1983;3:947–50.
Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology 2009;50:1392–402.
Saikia N, Talukdar R, Mazumder S, Khanna S, Tandon R. Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J 2007;83:32.
Alexopoulou A, Karayiannis P. HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection. World J Gastroenterol 2014;20:7644–52.
Widita H, Gunawan S, Laksono BT, Achwan WA, Wilusanta IG, Mahendra K, et al. HBeAg and anti HBe status in patients with chronic hepatitis B infection. Indones J Gastroenterol Hepatol Digest Endosc 2010;11:125–7.
Tapper EB, Lok AS-F. Use of liver imaging and biopsy in clinical practice. N Engl J Med 2017;377:756–68.
Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol 2015;10:473–510.
Bekki Y, Yoshizumi T, Shimoda S, Itoh S, Harimoto N, Ikegami T, et al. Hepatic stellate cells secreting WFA+-M2BP: its role in biological interactions with Kupffer cells. J Gastroenterol Hepatol 2017;32:1387–93.
Yongdi C. Meta-analysis of risk factors for development of liver cirrhosis in chronic hepatitis B patients. Glob J Infect Dis Clin Res 2018;x:004–9.
Yang Y, Wang L, Yan L, Zhang L, Zhou W, Chen Q, et al. Platelet count is closely associated with the severity of liver injury in patients with chronic hepatitis B virus infection: a cross-sectional study. Exp Ther Med 2020;20:243–50.
Carvalho JR, Machado MV. New insights about albumin and liver disease. Ann Hepatol 2018;17:547–60.
Mak LY, Wong DKH, Seto WK, Ning Q, Cheung KS, Fung J, et al. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. Hepatol Int 2019;13:148–56.
Ichikawa Y, Joshita S, Umemura T, Shobugawa Y, Usami Y, Shibata S, et al. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatol Res 2017;47:226–33.
Jekarl DW, Choi H, Lee S, Kwon JH, Lee SW, Yu H, et al. Diagnosis of liver fibrosis with Wisteria floribunda agglutinin positive Mac-2 binding protein (WFA-M2BP) among chronic hepatitis B patients. Ann Lab Med 2018;38:348–54.
Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, et al. Mac-2 binding protein glycosylation isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection. Hepatol Commun 2019;3:493–503.
Yamada N, Sanada Y, Tashiro M, Hirata Y, Okada N, Ihara Y, et al. Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia. J Gastroenterol 2017;52:245–52.
Ura K, Furusyo N, Ogawa E, Hayashi T, Mukae H, Shimizu M, et al. Serum WFA(+)-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther 2016;43:114–24.
Feng S, Wang Z, Zhao Y, Tao C. Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis. Sci Rep 2020;10:1–13.
Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, et al. Serum Wisteria floribunda agglutinin positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study. J Viral Hepat 2016;23:977–84.
Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, et al. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol 2015;13:772–9.
Kojiro M, Shimamatsu K, Kage M. Pathomorphologic comparison of hepatitis C virus-related and hepatitis B virus-related cirrhosis bearing hepatocellular carcinoma. Princess Takamatsu Symp 1995;25:179–84.
Ito K, Murotani K, Nakade Y, Inoue T, Nakao H, Sumida Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein levels and liver fibrosis: a meta-analysis. J Gastroenterol Hepatol 2017;32:1922–30.
Sturm N, Marlu A, Arvers P, Zarski JP, Leroy V. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C. Liver Int 2013;33:428–38.
Hsu YC, Jun T, Huang YT, Yeh ML, Lee CL, Ogawa S, et al. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. Aliment Pharmacol Ther 2018;48:1128–37.
Mak LY, Wong DKH, Seto WK, Ning Q, Cheung KS, Fung J, et al. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. Hepatol Int 2019;13:148–56.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson
IM, et al. Regression of cirrhosis during treatment with
tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year
open-label follow-up study. The Lancet 2013;381:468–75.
Schiff ER, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS,
et al. Long-term treatment with entecavir induces reversal of
advanced fibrosis or cirrhosis in patients with chronic hepatitis
B. Clin Gastroenterol Hepatol 2011;9:274–6.
Ishii A, Nishikawa H, Enomoto H, Iwata Y, Kishino K,
Shimono Y, et al. Clinical implications of serum Wisteria
floribunda agglutinin-positive Mac-2-binding protein
in treatment-naïve chronic hepatitis B. Hepatol Res
;47:204–15
Article Metrics
Abstract View
: 1148 times
Download : 62 times
DOI: 10.24871/241202312-22
Refbacks
- There are currently no refbacks.
